标题
Future novel therapeutic agents forClostridium difficileinfection
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 19, Issue 7, Pages 825-836
出版商
Informa Healthcare
发表日期
2010-06-04
DOI
10.1517/13543784.2010.495386
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas
- (2010) Z-D Jiang et al. JOURNAL OF CLINICAL PATHOLOGY
- Clostridium difficile— Beyond Antibiotics
- (2010) Lorraine Kyne NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with Monoclonal Antibodies againstClostridium difficileToxins
- (2010) Israel Lowy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection
- (2009) D.M. Citron et al. ANAEROBE
- Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe RefractoryClostridium difficileInfection
- (2009) Bjorn L. Herpers et al. CLINICAL INFECTIOUS DISEASES
- Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study
- (2009) Daniel M. Musher et al. CLINICAL INFECTIOUS DISEASES
- High Frequency of Rifampin Resistance Identified in an EpidemicClostridium difficileClone from a Large Teaching Hospital
- (2009) Scott R. Curry et al. CLINICAL INFECTIOUS DISEASES
- Activity of tigecycline against recent European clinical isolates of Clostridium difficile
- (2009) Stephen P. Hawser INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors
- (2009) F. Sundram et al. JOURNAL OF HOSPITAL INFECTION
- Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)
- (2009) Brett A. Leav et al. VACCINE
- Study of the In Vitro Activities of Rifaximin and Comparator Agents against 536 Anaerobic Intestinal Bacteria from the Perspective of Potential Utility in Pathology Involving Bowel Flora
- (2008) S. M. Finegold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile
- (2008) J. R. O'Connor et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile
- (2008) J. A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection
- (2008) T. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection
- (2008) T. J. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Treatment ofClostridium difficileInfection
- (2008) Dale N. Gerding et al. CLINICAL INFECTIOUS DISEASES
- Measures to Control and PreventClostridium difficileInfection
- (2008) Dale N. Gerding et al. CLINICAL INFECTIOUS DISEASES
- Executive Summary: Scientific and Regulatory Challenges of Development of Probiotics as Foods and Drugs
- (2008) Freddie Ann Hoffman et al. CLINICAL INFECTIOUS DISEASES
- Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study
- (2008) Kevin W. Garey et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A
- (2008) Claribel P. Taylor et al. VACCINE
- Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors
- (2007) X. Wu et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started